Surgical versus medical methods for second trimester induced abortion

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Lohr, Patricia A ^a   Hayes, J L ^a   Gemzell Danielsson, K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CONTRACEPTIVE AGENT; MIFEPRISTONE; MISOPROSTOL; OXYTOCIC AGENT; PROSTAGLANDIN F2 ALPHA;

BLEEDING; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CURETTAGE; DIARRHEA; DILATION AND EVACUATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; EMOTIONAL DISORDER; FATIGUE; GESTATION PERIOD; HEADACHE; HOSPITALIZATION; HUMAN; INDUCED ABORTION; INTERMETHOD COMPARISON; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; PAIN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECOND TRIMESTER ABORTION; SEIZURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VAGINAL INJURY;

EID: 44949214807     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006714.pub2     Document Type: Review

References (44)

1. Grimes 1980 {published data only} Grimes DA, Hulka JF, McCutchen ME. Midtrimester abortion by dilatation and evacuation versus intra-amniotic instillation of prostaglandin F2a: A randomized clinical trial. American Journal of Obstetrics and Gynecology 1980;137:785-90.
2. Grimes 2004 {published data only} Grimes DA, Smith SM, Witham AD. Mifepristone and misoprostol verus dilation and evacuation for midtrimester aboriton: a pilot randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology 2004;111:148-53.
3. Philips 1974 Philips FS, Ghouse N, Sundaravalli A. Comparative study of prostaglandin F2 alpha, hypertonic saline, and hysterotomy in the termination of mid-trimester pregnancies in Government Erskine Hospital from February 1st 1973 to October 31st 1973. Unpublished 20.
4. Ashok 1999 Ashok PW, Templeton A. Nonsurgical mid-trimester termination of pregnancy: a review of 500 cases. British Journal of Obstetrics and Gynaecology 1999;106:706-10.
5. Ashok 2002 Ashok PW, Kidd A, Flett GMM, Fitzmaurice A, Graham W, Templeton A. Randomized comparison of efficacy, acceptability and cost of medical versus surgical abortion. Human Reproduction 2002;17:92-8.
6. Ashok 2004 Ashok PW, Templeton A, Wagaarachchi PT, Flett GMM. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception 2004;69:51-8.
7. Autry 2002 Autry AM, Hayes EC, Jacobson GF, Kirby RS. A comparison of medical induction and dilation and evacuation for second-trimester abortion. American Journal of Obstetrics and Gynecology 2002;187:393-7.
8. Bartlett 2004 Bartlett LA. Berg CJ, Shulman HB, Zane SB, Green CA, Whitehead S, Atrash HK. Risk factors for legal induced abortion-related mortality in the United States. Obstetrics and Gynecology 2004;103:729-37.
9. Bygdeman 1983 Bygdeman M. Interruption of gestation: The state of the art and prospects for the future. Research on the regulation of human fertility. Needs of developing countries and priorities for the future. Stokholm: Scriptor, 1983:528-43.
10. Bygdeman 1985 Bygdeman M, Swahn ML. Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception 1985;32:45-51.
11. Caliskan 2005 Caliskan E, Dilbaz D. Doger E, Ozeren S, Dilbaz B. Randomized comparison of 3 misoprostol protocols for sbortion induction at 13-20 weeks of gestation. The Journal of Reproductive Medicine 2005;50:173-80.
12. Cates 1978 Cates W Jr, Grimes DA, Schulz KF, Ory HW, Tyler CW Jr. World health organization studies of prostagladins versus saline as abortifacients. Obstetrics and Gynecology 1978;52:493-8.
13. Cates 1982 Cates W Jr, Schulz KF, Grimes DA, Horowitz AJ, Lyon FA, Kravitz FH, et al.Dilatation and evacuation procedures and second-trimester abortions. The role of physician skill and hospital setting. Journal of the American Medical Association 1982;248:559-63.
14. Creinin 2000 Creinin MD. Randomized comparison of efficacy, acceptability and cost of medical versus surgical abortion. Contraception 2000;62:117-24.
15. Drey 2006 Drey EA, Foster DG, Jackson RA, Lee SJ, Cardenas LH, Darney PD. Risk factors associated with presenting for abortion in the second trimester. Obstetrics and Gynecology 2006;107:128-135.
16. Finer 2005 Finer LB, Henshaw SK. Estimates of U.S. abortion incidence in 2001 and 2002. http://www.guttmacher.org/pubs/2005/05/18/ ab_incidence.pdf (accessed 29 August 2006).
17. George 1996 George A, Randall S. Late presentation for abortion. British Journal of Family Planning 1996;22:12-15.
18. Goh 2006 Goh SE, Thong KJ. Induction of second trimester abortion (12-20 weeks) with mifepristone and misoprostol: a review of 386 consecutive cases. Contraception 2006;73:516-9.
19. Goldberg 2001 Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. New England Journal of Medicine 2001;344:38-47.
20. Grimes 1977 Grimes DA, Schulz KF, Cates W Jr, Tyler CW Jr. Mid-trimester abortion by dilatation and evacuation: a safe and practical alternative. New England Journal of Medicine 1977;296:1141-5.
21. Grimes 1984 Grimes DA, Schulz KF, Cates W Jr. Prevention of uterine perforation during curettage abortion. Journal of the American Medical Association 1984;251:2108-11.
22. Grimes 1985 Grimes DA, Schulz KF. Morbidity and mortality from second-trimester abortions. The Journal of Reproductive Medicine 1985;30:505-14.
23. Grimes 1998 Grimes, DA. The continuing need for late abortions. Journal of the American Medical Association 1998;280:747-50.
24. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Cochrane Database of Systematic Reviews 2005, Issue 3.
25. HMSO 1998 Department of Health, Welsh Office, Scottish Office Department of Health, and Department of Health and Social Services, Northern Ireland. Why Mothers Die. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom, 1994-1996. London: The Stationery Office, 1998.
26. Ingham 2007 Ingham R, Lee E, Clements S, Stone N. Second trimester abortion in England and Wales. http://www.psychology.soton.ac.uk/cshr, accessed August 14, 2007 2007.
27. Jain 1999 Jain JK, Kuo J, Mishell DR Jr. A comparison of two dosing regimens of intravaginal misoprostol for second-trimester pregnancy termination. Obstetrics and Gynecology 1999;93:571-5.
28. Kafrissen 1984 Kafrissen ME, Schulz KF, Grimes DA, Cates W Jr. Midtrimester abortion. Intra-amniotic instillation of hyperosmolar urea and prostaglandin F2 alpha v dilatation and evacuation. Journal of the American Medical Association 1984;251:916-9.
29. Ngai 2003 Ngai SW, Tang OS, Ho PC. Prostaglandins for induction of second-trimester termination and intrauterine death. Best Practice & Research Clinical Obstetrics & Gynaecology 2003;17:765-75.
30. Norman 1991 Norman JE, Thong KJ, Baird DT. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 1991;338:1233-6.
31. RCOG 2004 Royal College of Obstetricians and Gynaecologists. The Care of Women Requesting Induced Abortion. London: RCOG Press, 2004.
32. Rodger 1990 Rodger MW, Baird DT. Pretreatment with mifepristone (RU-486) reduces interval between prostaglandin administration and expulsion in second trimester abortion. British Journal of Obstetrics and Gynaecology 1990;97:41-5.
33. Schulz 1983 Schulz KF, Grimes DA, Cates W Jr. Measures to prevent cervical injury during suction curettage abortion. Lancet 1983;1:1182-5.
34. Siebert 2005 Siebert JR, Kapur RP, Resta RG, Luthy D. Methods for induced abortion [letter]. Obstetrics and Gynecology 2005;105:221.
35. Stakes 2006 STAKES. Official statistics of Finland. Induced abortions and sterilisations 2005. Statistical summary 2006.
36. Stat. Service 2005 Government Statistical Service. Abortion statistics, England and Wales: 2005. Statistical Bulletin 2006/01 July 4, 2006.
37. Strauss 2005 Strauss LT, Herndon J, Chang J, Parker WY, Bowens SV, Berg CJ. Abortion surveillance - United States, 2002. Morbidity and Mortality Weekly Report 2005;54:1-31.
38. Stubblefield 2004 Subblefield PG, Carr-Ellis S, Borgatta L. Methods for induced abortion. Obsterics and Gynecology 2004;104:174-85.
39. Stubblefield 2005 Stubblefield PG, Carr-Ellis S, Borgatta L. Methods for induced abortion [letter]. Obstetrics and Gynecology 2005;105:221-2.
40. Swahn 1988 Swahn ML, Bygdeman M. The effect of the antiprogestin RU486 on uterine contractility and sensitivity to prostaglandin and oxytocin. British Journal of Obstetrics and Gynaecology 1988;95:126-34.
41. Tang 2000 Tang OS, Ho PC. Medical abortion in the second trimester. Best Practice & Research Clinical Obstetrics and Gynaecology 2000;16:237-46.
42. Thong 1992 Thong KJ, Baird DT. A study of gemeprost alone, dilapan or mifepristone in combination with gemeprost for the termination of second trimester pregnancy. Contraception 1992;46:11-7.
43. Urquhart 1989 Urquhart DR, Bahzad C, Templeton AA. Efficacy of the antiprogestin mifepristone (RU 486) prior to prostaglandin termination of pregnancy. Human Reproduction 1989;4:202-3.
44. WHO 1997 Medical methods for termination of pregnancy. Report of a WHO Scientific Group. World Health Organization Technical Report Series 1997; Vol. 871.